| For: | Samanta A, Srivastava A. Biologics in the management of pediatric inflammatory bowel disease: When and what to choose. World J Clin Pediatr 2025; 14(1): 100938 [PMID: 40059900 DOI: 10.5409/wjcp.v14.i1.100938] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i1/100938.htm |
| Number | Citing Articles |
| 1 |
TJ Afaa, V Etwire, NA Anane-Binfoh, E Amoah, EO Darkwa, R Djagbletey. Biologic therapy for paediatric inflammatory bowel disease in Ghana: a case series. South African Journal of Gastroenterology and Hepatology 2026; 3(1) doi: 10.36303/SAJGH.4158
|
| 2 |
Serena Yun‐Chen Tsai, Ashwin N. Ananthakrishnan, Harland S. Winter, Kevin Sheng‐Kai Ma. Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation. Journal of Pediatric Gastroenterology and Nutrition 2026; 82(2) doi: 10.1002/jpn3.70251
|
| 3 |
Mohammed Al-Beltagi, Nermin Kamal Saeed, Yasser El-Sawaf, Adel Salah Bediwy, Reem Elbeltagi. Early-life gastrointestinal inflammation and the developing brain: Unravelling the pathways to long-term cognitive dysfunction. World Journal of Clinical Pediatrics 2026; 15(2): 117843 doi: 10.5409/wjcp.v15.i2.117843
|